Treatment of pervasive developmental disorders with redox-active therapeutics
View Patent ↗Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD—not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
1. A method of reducing a symptom associated with, or for treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD) in a patient in need of such treatment, comprising administering to the patient a therapeutically or physiologically effective amount of a compound of Formula III,
wherein,
the bonds indicated with a dashed line are independently single bonds or double bonds; and
R 1 , R 2 , and R 3 are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, halogen and CN;
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.
2. The method according to claim 1 , wherein the compound of Formula III has the formula:
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.
3. The method according to claim 2 , wherein the compound is:
or a stereoisomer, or a mixture of stereoisomers, a solvate or a hydrate thereof.
4. The method of claim 1 , wherein the bonds indicated with a dashed line are all single bonds.
5. The method of claim 1 , wherein the bonds indicated with a dashed line are all double bonds.
6. The method of claim 3 , wherein the bonds indicated with a dashed line are all single bonds.
7. The method of claim 3 , wherein the bonds indicated with a dashed line are all double bonds.
8. The method of claim 1 , wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, and (C 1 -C 6 )alkoxy.
9. The method of claim 1 , wherein R 1 , R 2 , and R 3 are independently selected from (C 1 -C 4 )alkyl.
10. The method of claim 1 , wherein R 1 , R 2 , and R 3 are methyl.
11. The method of claim 1 , wherein at least one of R 1 , R 2 , and R 3 is not methyl.
12. The method of claim 1 , wherein R 1 and R 2 are methoxy, and R 3 is methyl.
13. The method of claim 4 , wherein the method is for treating the PDD, wherein the PDD is autistic spectrum disorder (ASD).
14. The method according to claim 5 , wherein the method is for treating the PDD, wherein the PDD is autistic spectrum disorder (ASD).
15. The method of claim 6 , wherein the method is for treating the PDD, wherein the PDD is autistic spectrum disorder (ASD).
16. The method according to claim 7 , wherein the method is for treating the PDD, wherein the PDD is autistic spectrum disorder (ASD).
17. The method according to claim 4 , wherein the method is for treating attention deficit/hyperactivity disorder (ADHD).
18. The method according to claim 5 , wherein the method is for treating attention deficit/hyperactivity disorder (ADHD).
19. The method according to claim 6 , wherein the method is for treating attention deficit/hyperactivity disorder (ADHD).
20. The method according to claim 7 , wherein the method is for treating attention deficit/hyperactivity disorder (ADHD).
21. The method according to claim 6 , wherein the method is for treating Rett's disorder.
22. The method according to claim 7 , wherein the method is for treating Rett's disorder.